Further benefits by early start of HIV treatment in low income countries: Survival estimates of early versus deferred antiretroviral therapy

Abstract

International HIV guidelines have recently shifted from a medium-late to an early-start treatment strategy. As a consequence, more people will be eligible to Highly Active Antiretroviral Therapy (HAART). We estimate mean life years gained using different treatment indications in low income countries.